shutterstock_619078730_melinda_nagy

Melinda Nagy / Shutterstock.com

8 April 2021Big PharmaMuireann Bolger

UK govt’s £20m fund for life sciences opens for applications

The UK government’s £20 million fund aimed at growing life sciences manufacturing is now open for applications, it confirmed today, April 7.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More on this story

UK could lose out on Europe-wide drug safety system post-Brexit

12 February 2019 UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

UK court overturns Genentech patent, cites Brexit in CJEU referral

1 March 2019 The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks